Ubs Group Ag Cure Vac N.V. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Cure Vac N.V. stock. As of the latest transaction made, Ubs Group Ag holds 843,193 shares of CVAC stock, worth $3.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

843,193

Previous 576,897 46.16%

Holding current value

$3.77 Million

Previous $1.97 Million 18.71%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$2.77 - $4.68 $737,639 - $1.25 Million	266,296 Added 46.16%	843,193 $2.34 Million
Q4 2024 Feb 14, 2025	BUY	$2.49 - $3.41 $1.29 Million - $1.76 Million	517,223 Added 866.75%	576,897 $1.97 Million
Q3 2024 Nov 14, 2024	SELL	$2.74 - $3.79 $146,036 - $201,999	-53,298 Reduced 47.18%	59,674 $175,000
Q2 2024 Aug 13, 2024	SELL	$2.31 - $4.99 $1.37 Million - $2.95 Million	-591,219 Reduced 83.96%	112,972 $384,000
Q1 2024 May 13, 2024	BUY	$2.94 - $4.34 $1.68 Million - $2.48 Million	572,319 Added 434.0%	704,191 $2.13 Million
Q4 2023 Feb 09, 2024	BUY	$3.96 - $6.41 $223,011 - $360,985	56,316 Added 74.54%	131,872 $555,000
Q3 2023 Nov 09, 2023	SELL	$6.5 - $10.77 $85,800 - $142,164	-13,200 Reduced 14.87%	75,556 $516,000
Q2 2023 Aug 11, 2023	SELL	$6.69 - $12.25 $531,935 - $974,022	-79,512 Reduced 47.25%	88,756 $924,000
Q1 2023 May 12, 2023	BUY	$6.38 - $12.5 $522,930 - $1.02 Million	81,964 Added 94.97%	168,268 $1.17 Million
Q4 2022 Feb 08, 2023	BUY	$5.75 - $8.5 $150,092 - $221,875	26,103 Added 43.36%	86,304 $520,000
Q3 2022 Nov 10, 2022	BUY	$7.48 - $15.24 $228,327 - $465,201	30,525 Added 102.86%	60,201 $475,000
Q2 2022 Aug 10, 2022	BUY	$13.18 - $19.41 $321,367 - $473,274	24,383 Added 460.67%	29,676 $403,000
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $1,517 - $3,630	103 Added 1.98%	5,293 $104,000
Q4 2021 Feb 14, 2022	BUY	$33.72 - $48.22 $55,503 - $79,370	1,646 Added 46.44%	5,190 $178,000
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $5.42 Million - $8.2 Million	-110,087 Reduced 96.88%	3,544 $193,000
Q2 2021 Aug 13, 2021	BUY	$56.91 - $127.53 $6.24 Million - $14 Million	109,646 Added 2751.47%	113,631 $8.35 Million
Q1 2021 May 12, 2021	BUY	$79.79 - $126.29 $33,830 - $53,546	424 Added 11.91%	3,985 $364,000
Q4 2020 Feb 11, 2021	BUY	$46.76 - $136.27 $109,698 - $319,689	2,346 Added 193.09%	3,561 $288,000
Q3 2020 Nov 12, 2020	BUY	$43.8 - $77.2 $53,217 - $93,798	1,215 New	1,215 $57,000

Others Institutions Holding CVAC

# of Institutions

Shares Held

10.7M

Call Options Held

75.1K

Put Options Held

86.7K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $838M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account